



Allergy Therapeutics plc
("Allergy Therapeutics" or "the Group")

Directorate Change

Appointment of David Ball as Non-Executive Director

27 June 2024 Allergy Therapeutics (AIM: AGY), the fully integrated commercial biotechnology company specialising in allergy vaccines, today announces that David Ball will join the Board of Allergy Therapeutics as an independent Non-Executive Director with immediate effect. David is also appointed Chair of the Board's Audit and Risk Committee.

David has over 25 years of experience in financial markets, including 15 years as an equity portfolio manager and partner with Tudor Investment Corporation. David is a chartered accountant and holds undergraduate and postgraduate degrees in engineering from Cambridge University.

Peter Jensen, Chairman of Allergy Therapeutics, said: *"I am delighted to announce David's appointment and welcome him to the Board at this exciting and positive time for the Company. David has an impressive breadth of executive and financial markets experience, and we look forward to his contributions to the Board and oversight of our Audit and Risk Committee."*

Commenting on his appointment, David Ball said: *"I am delighted to be joining the Board of Allergy Therapeutics and look forward to working with my fellow Board members and the wider team to further develop Allergy's leading position in the sector."*

Additional Information in respect of the AIM Rules:

David William Dawson Ball, aged 55, is a director of Argonaute RNA Limited and in the previous five years, David was a director of Brainomix Limited. David does not have an interest in ordinary shares in the Company. The Company confirms that there is no other information in relation to David Ball's appointment that is required to be disclosed pursuant to Rule 17 or Schedule Two paragraph (g) of the AIM Rules for Companies.

- ENDS -

For further information, please contact:

Allergy Therapeutics

Manuel Llobet, Chief Executive Officer
Shaun Furlong, Chief Financial Officer
+44 (0)1903 845 820

Panmure Gordon (Nominated Adviser and Broker)

Emma Earl, Will Goode, Freddy Crossley, Mark Rogers, Corporate Finance
Rupert Dearden, Corporate Broking
+44 (0)20 7886 2500

ICR Consilium

Mary-Jane Elliott / David Daley / Davide Salvi
+44 (0)20 3709 5700
allergytherapeutics@consilium-comms.com

Notes for editors:

About Allergy Therapeutics

Allergy Therapeutics is an international commercial biotechnology company, headquartered in the UK, focussed on the treatment and diagnosis of allergic disorders, including aluminium free immunotherapy vaccines that have the potential to cure disease. The Group sells proprietary and third-party products from its subsidiaries in nine major European countries and via distribution agreements in an additional ten countries. For more information, please see www.allergytherapeutics.com.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@seg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

BOADZGZVGVGGDZZ